Skip to content
Menu

Rafael Holdings, Inc. RFL

Full chart Compare
Set alert

Price alert · RFL

All alert types
0.92 USD +0.02 (+2.19%)

Regular-session close

0.92 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

0.8001 Day range 0.9691
0.8001 52-week range 3.96
YTD
-22.06%
1 year
-25.83%

 

No chart data for this range yet.
Market cap
47.99M
Revenue (ttm)
637.00K
EPS (ttm)
-0.58
Shares out
28.95M
YTD return
-22.06%
1-year return
-25.83%
50-day average
1.90
Volume
156.49K
Avg volume
140.61K
Open
0.781
Previous close
0.90
Day's range
0.8001 – 0.9691
52-week range
0.8001 – 3.96
Beta
1.07

Key statistics

200-day average
1.68
Enterprise value
49.55M
Price / sales
88.23
Price / book
0.57
Revenue growth
142.60%
Total cash
2.67M
Total debt
2.39M
Return on equity
-71.08%
Short % of float
0.19%

Fundamental scorecard

6 of 25 checks passed on RFL’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 1 of 5
  • Growth 1 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Jul 31, 2026.

Financials — quick view

All financials
RFL Revenue — quarterly 244.00K
RFL Net income — quarterly -9.18M
RFL EPS — quarterly -0.18

Earnings

RFL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Dec 11, 2024Oct 1, 20240.00-0.37——
Nov 6, 2024Jul 1, 20240.00-0.19——
Jun 14, 2024Apr 1, 20240.00-1.36——
Mar 13, 2024Jan 1, 20240.00-0.08——
Dec 14, 2023Oct 1, 20230.00-0.08——
Oct 30, 2023Jul 1, 20230.000.06——

About Rafael Holdings, Inc.

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), a stable analog of transient, acylated catalytic intermediates of lipoate currently under phase 2 open-label multi-cohort study evaluating CPI-613 in combination with hydroxychloroquine and 5-fluorouracil or gemcitabine in patients with advanced chemorefractory colorectal, pancreatic, or other solid cancers; and under phase 1 dose-escalation study of CPI-613 in combination with chemoradiation in patients with pancreatic adenocarcinoma. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

Sector
Real Estate
Industry
Real Estate Services
Country
United States

News

Your note

Sign in to keep a note on RFL — it syncs with the Stock Master app.

Insider holders

RFL insider holders
InsiderRelationLatest transactionDateShares held
CONKLING WILLIAMChief Executive OfficerStock Award(Grant)Oct 24, 2023563,119
GREENBERG STEPHEN MDirectorStock Award(Grant)Jan 4, 202474,950
JONAS HOWARD SOfficer and DirectorStock Award(Grant)Jun 12, 20244,047,180
MCCAMISH MARK ANTHONYDirectorStock Award(Grant)Jan 4, 202460,241
PASCHE BORIS CDirectorStock Award(Grant)Jan 4, 202347,295
POLINSKY DAVIDChief Financial OfficerStock Award(Grant)Oct 24, 2023168,239

Institution ownership

RFL institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc2.95%705,0251.33MSep 29, 2024
Dimensional Fund Advisors LP1.42%338,426639.63KSep 29, 2024
Acuitas Investments LLC1.18%281,659532.34KSep 29, 2024
Kahn Brothers Group Inc.1.12%267,596505.76KSep 29, 2024
Blackrock Inc.0.85%202,301382.35KSep 29, 2024
Geode Capital Management, LLC0.62%148,068279.85KSep 29, 2024

Fund ownership

RFL fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund2.14%511,989967.66KSep 29, 2024
Vanguard Extended Market Index Fund0.72%172,498326.02KSep 29, 2024
DFA U.S. Micro Cap Series0.48%114,197215.83KJul 30, 2024
Fidelity Extended Market Index Fund0.40%96,179181.78KOct 30, 2024
Bridgeway Funds Inc-Ultra Small Company Market Fund0.22%51,65697.63KSep 29, 2024
iShares Micro Cap ETF0.14%32,95162.28KOct 30, 2024